Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients

"3 cycles of BvC treatment for all enrolled patients.~Brentuximab vedotin; Specification: 50mg per vial; 1.8mg/kg qd d1 every 3 weeks, ivgtt.;~Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks every 3 weeks, po.;"

"Consolidation therapy( For patients who achieved CR after induction therapy, 3 cycles of additional BvC treatment; For patients who achieved PR after induction therapy, 6 cycles of additional BvC treatment).~Brentuximab vedotin; Specification: 50mg per vial; 1.8mg/kg qd d1 every 3 weeks, ivgtt.;~Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks every 3 weeks, po.;~Maintenance therapy chidamide (20mg biw for 2 weeks every 3 weeks, po.) for ≥2 years"

Chidamide (20mg biw for 2 weeks every 3 weeks, po.) for ≥2 years